Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRT 2584 XX in Moderate to Severe Plaque Psoriasis
NCT00333411Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2006
- Primary completion
- Jun 2008
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of BIRT 2584 XX in plaque psoriasis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Psoriasis Area and Severity Index 75% reduction at 12 weeks. Started Jun 2006; status: completed.
02
Drugs
BIRT 2584 XX
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00333411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00333411.